Evidence map›Paper›PMID 25089563›Full record

ArticleAntioxidants & redox signaling2015

The angiotensin-converting enzyme 2/angiotensin (1-7)/Mas axis protects against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived ROS-mediated RhoA/Rho kinase pathway.

Ying Meng, Ting Li, Gao-Su Zhou, Yan Chen, Chang-Hui Yu, Miao-Xia Pang, Wei Li, Yang Li, Wen-Yong Zhang, Xu Li

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Antioxidants & redox signaling, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04331470 (Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease), which is not on this map. Cited by 86 papers.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04331470 phase2 / phase3unknown statusnot on this mapstarted 2020, after this paper: background citation

Evaluation of Efficacy of Pharmacotherapy Treatment of COVID- 19 Infection Using Oral Levamisole and Formoterol+Budesonide Inhaler and Comparison of This Treatment Protocol With Standard National Treatment of the Disease

TypeinterventionalSponsorFasa University of Medical SciencesRan2020 to 2020Enrolled30ConditionsCOVID-19ArmsLevamisole Pill + Budesonide+Formoterol inhaler, Lopinavir/Ritonavir + hydoxychloroquine
3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 153 citations in OpenAlex.

  1. Imbalance of renin-angiotensin system in calcium oxalate crystals-induced renal oxidative stress and autophagy.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. The RAAS Goodfellas in Cardiovascular System.Journal of clinical medicine · 2023
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. The Role of Tβ4-POP-Ac-SDKP Axis in Organ Fibrosis.International journal of molecular sciences · 2022
    Review
  18. Review
  19. Metal-based complexes against SARS-CoV-2.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2022
    Review
  20. Development of Metal Complexes for Treatment of Coronaviruses.International journal of molecular sciences · 2022
    Article

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ying Meng1 Department of Respiratory Diseases, Nanfang Hospital, the Southern Medical University , Guangzhou, China .
Ting Li
Gao-Su Zhou
Yan Chen
Chang-Hui Yu
Miao-Xia Pang
Wei Li
Yang Li
Wen-Yong Zhang
Xu Li
Southern Medical University · CNThe Military General Hospital of Beijing PLA · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledReactive oxygen species (ROS) generated by NADPH oxidase-4 (NOX4) have been shown to initiate lung fibrosis. The migration of lung fibroblasts to the injured area is a crucial early step in lung fibrosis. The angiotensin-converting enzyme 2 (ACE2)/angiotensin (1-7) [Ang(1-7)]/Mas axis, which counteracts the ACE/angiotensin II (AngII)/angiotensin II type 1 receptor (AT1R) axis, has been shown to attenuate pulmonary fibrosis. Nevertheless, the exact molecular mechanism remains unclear.

aimsTo investigate the different effects of the two axes of the renin-angiotensin system (RAS) on lung fibroblast migration and extracellular matrix accumulation by regulating the NOX4-derived ROS-mediated RhoA/Rho kinase (Rock) pathway.

resultsIn vitro, AngII significantly increased the NOX4 level and ROS production in lung fibroblasts, which stimulated cell migration and α-collagen I synthesis through the RhoA/Rock pathway. These effects were attenuated by N-acetylcysteine (NAC), diphenylene iodonium, and NOX4 RNA interference. Moreover, Ang(1-7) and lentivirus-mediated ACE2 (lentiACE2) suppressed AngII-induced migration and α-collagen I synthesis by inhibiting the NOX4-derived ROS-mediated RhoA/Rock pathway. However, Ang(1-7) alone exerted analogous effects on AngII. In vivo, constant infusion with Ang(1-7) or intratracheal instillation with lenti-ACE2 shifted the RAS balance toward the ACE2/Ang(1-7)/Mas axis, alleviated bleomycin-induced lung fibrosis, and inhibited the RhoA/Rock pathway by reducing NOX4-derived ROS. INNOVATION: This study suggests that the ACE2/Ang(1-7)/Mas axis may be targeted by novel pharmacological antioxidant strategies to treat lung fibrosis induced by AngII-mediated ROS.

conclusionThe ACE2/Ang(1-7)/Mas axis protects against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived ROS-mediated RhoA/Rock pathway.

Indexed as

Cell MovementAngiotensin-Converting Enzyme 2Angiotensin IAnimalsCells, CulturedCollagen Type ICollagen Type I, alpha 1 ChainFibroblastsMaleNADPH Oxidase 4NADPH OxidasesPeptide FragmentsPeptidyl-Dipeptidase AProto-Oncogene MasProto-Oncogene ProteinsPulmonary FibrosisAce2 protein, ratAngiotensin-Converting Enzyme 2Angiotensin Iangiotensin I (1-7)Collagen Type ICollagen Type I, alpha 1 ChainNADPH Oxidase 4NADPH OxidasesNox4 protein, ratPeptide FragmentsPeptidyl-Dipeptidase AProto-Oncogene MasProto-Oncogene ProteinsReactive Oxygen SpeciesReceptors, G-Protein-CoupledrhoA GTP-Binding Proteinrho-Associated Kinases

Identifiers

PMID25089563
PMCPMC4283064
OpenAlexW2070459088

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.